Neil McFarlane
Director Ejecutivo en ZEVRA THERAPEUTICS, INC. .
Fortuna: 2 M $ al 30/04/2024
Cargos activos de Neil McFarlane
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Director/Miembro de la Junta | 06/04/2022 | - |
| Independent Dir/Board Member | 06/04/2022 | - | |
| ZEVRA THERAPEUTICS, INC. | Director/Miembro de la Junta | 10/10/2023 | - |
| Director Ejecutivo | 10/10/2023 | - | |
| Presidente | 10/10/2023 | - |
Historial de carrera de Neil McFarlane
Antiguos cargos conocidos de Neil McFarlane.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| Adamas Pharmaceuticals, Inc. | Director/Miembro de la Junta | 01/09/2019 | 01/11/2021 |
| Director Ejecutivo | 01/09/2019 | 01/11/2021 | |
| ADAMAS PHARMACEUTICALS, INC. | Director Ejecutivo | 16/09/2019 | 01/01/2021 |
| TRAVERE THERAPEUTICS, INC. | Director de Operaciones | 15/08/2016 | 31/05/2019 |
UCB, Inc.
 UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Corporate Officer/Principal | 01/01/2011 | 01/01/2016 |
Formación de Neil McFarlane.
| University of Florida | Graduate Degree |
Estadísticas
Internacional
| Estados Unidos | 8 |
Operativa
| Chief Executive Officer | 3 |
| Director/Board Member | 3 |
| Chief Operating Officer | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 2 |
| Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| TRAVERE THERAPEUTICS, INC. | Health Technology |
| COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
| ZEVRA THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Finance |
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
| Adamas Pharmaceuticals, Inc. |
- Bolsa de valores
- Insiders
- Neil McFarlane
- Experiencia